AZD 4547

Drug Profile

AZD 4547

Alternative Names: AZD4547

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Leeds; University of Wisconsin-Madison
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Gastric cancer; Lung cancer; Mesothelioma; Oesophageal cancer
  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Bladder cancer
  • Preclinical Head and neck cancer
  • No development reported Urogenital cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 AstraZeneca completes the phase II RADICAL trial in Breast cancer in United Kingdom (PO) (NCT01791985)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top